Dianthus Therapeutics (DNTH) Cash from Operations (2017 - 2025)

Dianthus Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 30555000.0 for Q3 2025.

• On a quarterly basis, Cash from Operations fell 43.67% year-over-year to 30555000.0 in Q3 2025; TTM through Sep 2025 was 109521000.0, a 74.98% decrease from a year earlier, with the FY2024 full-year figure at 78180000.0, down 112.09% from the prior year.
• Cash from Operations retreated to 30555000.0 in Q3 2025 per DNTH's latest filing, from 23892000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 16375000.0 in Q3 2022 and bottomed at 30555000.0 in Q3 2025.
• The 5-year median for Cash from Operations is 14941000.0 (2024), against an average of 15037842.11.
• Across the five-year window, Cash from Operations jumped 216.41% in 2022 and sank 207.08% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 15690000.0 in 2021, then surged by 43.59% to 8851000.0 in 2022, then sank by 33.93% to 11854000.0 in 2023, then plunged by 131.52% to 27444000.0 in 2024, then declined by 11.34% to 30555000.0 in 2025.
• Per Business Quant, the three latest DNTH Cash from Operations figures stand at 30555000.0 (Q3 2025), 23892000.0 (Q2 2025), and 27630000.0 (Q1 2025).